What effect does Donepezil have on intraocular pressure (IOP)?

Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase, primarily used in the treatment of Alzheimer's disease. Its pharmacological profile can affect various body systems, including the ocular system.

The correct answer indicates that Donepezil decreases intraocular pressure (IOP). This effect can be attributed to the increased availability of acetylcholine due to the inhibition of its breakdown. Acetylcholine, acting on muscarinic receptors in the eye, facilitates the outflow of aqueous humor through the trabecular meshwork and enhances the drainage of intraocular fluid. As a result, this mechanism contributes to a reduction in IOP, making Donepezil potentially beneficial for patients at risk for conditions like glaucoma.

Understanding the role of acetylcholine in ocular fluid dynamics helps clarify the relationship between Donepezil and IOP. The evidence supporting this effect has made Donepezil a topic of interest in treating or managing elevated IOP conditions, although its primary indication remains neurological.